Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "London"

64 News Found

Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis
Clinical Trials | April 15, 2025

Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis

More than 40 types of Amyloid proteins are discovered till date


GlaxoSmithkline Pharmaceuticals appoints Carson Dalton as Executive VP - Communications and Government Affairs
People | March 04, 2025

GlaxoSmithkline Pharmaceuticals appoints Carson Dalton as Executive VP - Communications and Government Affairs

Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability


Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences
People | February 23, 2025

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025


Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Drug Approval | December 14, 2024

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months


Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
People | November 21, 2024

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer


Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
Clinical Trials | September 16, 2024

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival


Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024
News | August 27, 2024

Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024

New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases


Imfinzi improved event-free survival and overall survival for bladder cancer
Clinical Trials | June 26, 2024

Imfinzi improved event-free survival and overall survival for bladder cancer

First immunotherapy regimen before and after surgery to extend survival in bladder cancer


Bayer aims to enhance performance and regain strategic flexibility by 2026
News | March 06, 2024

Bayer aims to enhance performance and regain strategic flexibility by 2026

Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis